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Abstract
Background: Clostridium difficile is the major cause of nosocomial antibiotic-associated diarrhoea with the potential
risk of progressing to severe clinical outcomes including death. It is not unusual for Clostridium difficile infection to
progress to complications of toxic megacolon, bowel perforation and even Gram-negative sepsis following
pathological changes in the intestinal mucosa. These complications are however less commonly seen in
community-acquired Clostridium difficile infection than in hospital-acquired Clostridium difficile infection. To the best
of our knowledge, this was the first case of community-acquired Clostridium difficile infection of its type seen in
Jamaica.
Case presentation: We report a case of a 22-year-old female university student who was admitted to the
University Hospital of the West Indies, Jamaica with a presumptive diagnosis of pseudomembranous colitis PMC.
She presented with a 5-day history of diarrhoea following clindamycin treatment for coverage of a tooth extraction
due to a dental abscess. Her clinical condition deteriorated and progressed from diarrhoea to toxic megacolon,
bowel perforation and Gram-negative sepsis. Clostridium difficile NAP12/ribotype 087 was isolated from her stool
while blood cultures grew Klebsiella pneumoniae. Despite initial treatment intervention with empiric therapy of
metronidazole and antibiotic clearance of Klebsiella pneumoniae from the blood, the patient died within 10 days of
hospital admission.
Conclusions: We believe that clindamycin used for coverage of a dental abscess was an independent risk factor
that initiated the disruption of the bowel micro-flora, resulting in overgrowth of Clostridium difficile NAP12/ribotype
087. This uncommon strain, which is the same ribotype (087) as ATCC 43255, was apparently responsible for the
increased severity of the infection and death following toxic megacolon, bowel perforation and
pseudomembranous colitis involving the entire large bowel. K. pneumoniae sepsis, resolved by antibiotic therapy
was secondary to Clostridium difficile infection. The case registers community-acquired Clostridium difficile infection
as producing serious complications similar to hospital-acquired Clostridium difficile infection and should be treated
with the requisite importance.
Keywords: Clostridium difficile, Klebsiella pneumoniae, Community-Acquired Infection, Diarrhoea, Clindamycin,
Pseudomembranous Colitis, Toxic Megacolon
* Correspondence: orville.heslop@uwimona.edu.jm
†Equal contributors
1Department of Microbiology, University of the West Indies, Kingston,
Jamaica
Full list of author information is available at the end of the article
© 2013 Heslop et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Heslop et al. BMC Infectious Diseases 2013, 13:299
http://www.biomedcentral.com/1471-2334/13/299
Background
Clostridium difficile (C. difficile) is the major cause of
nosocomial antibiotic-associated diarrhoea [1,2], while
secondary Gram-negative shock in community-acquired
Clostridium difficile infection (CA-CDI) may occur fol-
lowing bowel perforation in hospitalised patients [3].
CA-CDI is defined as symptoms that occur in the com-
munity or within 48 hours of admission to a hospital,
provided symptoms from onset were > 12 weeks after
the last discharge from a hospital [3]. CA-CDI occurs
less frequently than hospital-acquired C. difficile infec-
tion (HA-CDI). It is usually less severe and presents
more frequently among females with a median age of
50 years compared to 72 years with HA-CDI [3]. The
most common risk factors associated with CDI are
broad-spectrum antibiotics including third generation
cephalosporins, clindamycin, penicillins and, more re-
cently, fluoroquinolones [2,4]. However, virtually all anti-
biotics are potential risk factors for CDI [5]. We
highlight the unusual strain C. difficile ribotype 087 and
pulsed-field gel electrophoresis (PFGE) type 0515 asso-
ciated with severe complicated CDI, which was being
seen for the first time in Jamaica. Klebsiella pneumoniae
(K. pneumonia) sepsis, a subsequent clinical outcome,
was diagnosed from positive blood cultures after a 5-
day history of apparent clindamycin-induced diarrhoea
in CA-CDI.
Case presentation
A 22-year-old female presented to the University Hos-
pital of the West Indies, Jamaica for further investiga-
tion and management following transfer from a local
Government hospital where she presented with a 5-day
history of diarrhoea and fever. The diarrhoea com-
menced 5 days after starting clindamycin therapy for a
recent tooth extraction due to a dental abscess. Despite
discontinuation of clindamycin therapy and the intro-
duction of chloramphenicol and metronidazole empiric
therapy, the diarrhoea and fever continued.
Physical examination of the patient revealed a febrile
female in severe cardiopulmonary distress with tachycar-
dia, HR beats/150 min, and blood pressure 150/
100 mm/Hg. Laboratory investigations showed haemo-
globin of 10.4 gm/dl, white cell count of 2.1 × 109/litre,
and platelet count of 182 × 109/litre. Diarrhoea persisted
and progressed to toxic megacolon and bowel perforation.
Blood cultures (brain heart infusion and thioglycollate
broths) collected on admission grew K. pneumoniae from
all four bottles after 24 hours incubation at 37°C. Diar-
rhoeal stool specimen sent the day after admission was
positive for C. difficile toxin A/B (ELISA; Alexon Inc. 1190
Borregas Ave., Sunnyvale, CA. 94089–1302) and the cor-
responding organism isolated on selective culture
medium, cycloserine, cefoxitin, fructose agar (CCFA).
In the interim period of empiric therapy, susceptibility
testing on K. pneumoniae by the Kirby Bauer disc diffu-
sion method showed susceptibilities to ceftriaxone, co-
trimoxazole, ceporin, amikacin, gentamicin, ceftazidine,
and augmentin, as well as resistance to chloramphenical,
piperacillin and ampicillin. The patient continued therapy
on intravenous metronidazole and with the introduction
of ceftriaxone and gentamycin she became afebrile with
subsequent blood cultures becoming sterile. Hypotension,
pulmonary oedema, leucopenia, and thrombocytopenia
persisted despite appropriate therapy and intensive care
management. The patient died 10 days after hospital ad-
mission and an autopsy was performed. The most signifi-
cant finding of the autopsy was multiple discrete plaques
of yellowish exudate on the mucosal surface of the entire
large bowel typical of pseudomembranous colitis (PMC),
which was florid. Another noteworthy pathologic finding
was that of markedly overweight lungs with features in
keeping with adult respiratory distress syndrome.
Polymerase chain reaction (PCR) was used to confirm
the presence of C. difficile triphosphate isomerase (tpi),
toxin genes tcdA and tcdB, the lack of binary toxin cdtB
gene, and no deletion in tcdC gene [6]. PCR ribotyping
on the isolate revealed a ribotype of 087 and the pulsed-
field gel electrophoresis (PFGE) macrorestriction pattern
identified a fingerprint type 0515, not previously seen
using this method, and when compared to a national
collection of over 700 unique fingerprint types from
more than 7,100 CDI isolates (Figure 1). However, the fin-
gerprint pattern was closely related to the North Ameri-
can Pulsotype (NAP) NAP12 strain with only a one band
difference (Figure 1). The minimal inhibitory concentra-
tions (MIC) determined by Etest were as follows: sus-
ceptible to metronidazole 0.094 ug/ml; vancomycin
1 ug/ml; moxifloxacin 1 ug/ml; rifampicin < 0.002 ug/ml;
tigecycline 0. 125 ug/ml; and resistant to clindamycin
256 ug/ml. K. pneumoniae was isolated from 2 sets of
blood cultures following overnight incubation at 37°C.
The severe clinical outcomes seen in the present case
were not unusual though more commonly seen in HA-
CDI [3]. In addition to these clinical presentations, asso-
ciated hypotension and admission to the intensive care
unit classified this patient as a severe complicated case
of CDI [7]. In a large study covering the period 1991–
2005 in Olmsted County, Minnesota, it was interesting
to note that only 4% of CA-CDI had progressed to se-
vere complicated CDI [8]. It was further noted that such
cases are usually associated with a significantly older age
group with a median age of 80 years [8]. The manifested
clinical involvements along with a significant age differ-
ence are important features to consider in CA-CDI and
should serve to alert clinicians that there is always a po-
tential risk of young adults progressing to severe compli-
cated CDI. The source of K. pneumoniae sepsis in the
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patient was presumably the gastrointestinal tract, as there
were no symptoms or signs to suggest other systems in-
volvement. Notwithstanding treatment with metronida-
zole, the patient was unresponsive and progressed to toxic
megacolon and bowel perforation. These were probably
due to the failure to administer appropriate and adequate
clinical and surgical interventions.
Oral metronidazole remained the preferred first line
drug for treatment while vancomycin is reserved for se-
verely ill patients and recurrence of C. difficile colitis [9].
Interestingly, these interventions including the use of ad-
junctive intracolonic vancomycin therapy and total col-
ectomy, as recommended options, were not followed in
the management of the present case. It is important to
note that PMC was confirmed by autopsy. The failure to
apply the optimal required clinical and surgical interven-
tions during the patient’s hospitalisation were probably
due to the rapid progression of these clinical outcomes.
With the exception of toxins A and B produced by this
isolate, there was no deletion observed in the negative
regulator tcdC gene suggesting normal toxin expression.
However, ATCC 43255, which also has a wild type tcdC,
has shown increased toxin expression [10]. Importantly,
ATCC 43255 has the same ribotype (087) as the clinical
isolate and only a single band difference in the DNA
fingerprints was observed between the two isolates
(Figure 1). Based on the similarity of ribotypes and fin-
gerprint patterns between the two isolates, one could
speculate that the rapid progression to PMC in the pa-
tient may be due to increased toxin expression.
Ribotype 087 is the predominant strain in Hungary but
is uncommon internationally [11].
The patient had no history of hospitalisation 12 months
prior to infection and no health care-associated risk fac-
tors to CDI were noted. On the contrary, this young adult
female was actively pursuing a university education, which
was disrupted by CA-CDI [3]. The progression to toxic
megacolon in the patient was not a predicted clinical
outcome even after hospitalisation. The presence of a
perforated colon was a clear indication for surgical
intervention, especially if there were unresponsiveness to
other treatments and if clinical improvement was not
noted within 2 to 3 days of patient management [12].
Conclusions
To the best of our knowledge, this was the first case of
CA-CDI of its type seen in Jamaica, and was fraught
with many challenges including diagnosis and clinical
management. The clinical manifestations of CA-CDI
rapidly progressed to serious complications but were not
given the appropriate and timely treatment interven-
tions. We believe that clindamycin used for coverage of
a dental abscess was an independent risk factor that ini-
tiated the disruption of the bowel micro-flora resulting
in overgrowth of NAP12/ribotype 087. This was appar-
ently responsible for the increased severity of CDI seen
in the patient. The progression to death was the result
of complications from florid PMC while K. pneumoniae
sepsis was secondary to bowel perforation initiated by
pathological changes in the intestinal mucosa.
These findings underscore two important points that
clinicians should note: [1] the need to use clindamycin
more discriminately in spite of its excellent coverage as
a broad-spectrum antibiotic, and [2] to be more alert in
recognising the potential risk of CA-CDI progressing to
severe complicated CDI in young adults. Additionally,
clinicians and other healthcare providers should be
prudent to employ appropriate patient management to
reduce the morbidity and mortality rate among
hospitalised C. difficile infected individuals.
Consent
Written informed consent was obtained from the par-
ents of the patient for publication of this Case report
and any accompanying images. A copy of the written
consent is available for review from the Series Editor of
this journal.
The investigation of C. difficile infection whether ac-
quired in a hospital or in the community is an ongoing re-
search study, approved by the UHWI Ethics Committee.
Figure 1 Dendrogram depicting the Smal C. difficile fingerprint patterns from isolates used in this study; N10-01734 (clinical isolate);
09ACD0005 (typical NAP12 isolate); ATCC43255 (reference strain). The dendrogram was generated using BioNumerics v 3.5 (Applied Maths,
Belgium) using a band tolerance of 1.0%.
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The present case study would be included even though
this particular case occurred sometime before we received
ethical approval. Please see attached letter from the
UHWI Ethics Committee.
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